Login / Signup

Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States.

Daniel MolnarElizabeth M LaFrederik VerelstSara PostonJonathan GrahamLaure-Anne Van BellinghenDesmond Curran
Published in: Infectious diseases and therapy (2024)
These findings highlight the potential of the adjuvanted RSVPreF3 vaccine to substantially reduce RSV disease burden among US older adults aged ≥ 60 years.
Keyphrases
  • respiratory syncytial virus
  • public health
  • physical activity
  • human health
  • global health
  • climate change